Molecular Imaging of Cancer and Its Response to Therapy

该程序测试分子成像变量，它们如何预测对治疗的反应，以及它们在不同治疗过程中如何变化。我们提出了5个互动项目：1。增殖研究，以验证FLT与TdR相比在各种肿瘤患者中的效果如何，并探索简化PET程序的方法，同时仍然区分通量和运输。我们的假设是，FLT与适当的数据分析可以作为准确的TdR报告肿瘤增殖。我们将检验FLT PET加MRI可以区分完成体外放射治疗加同步TMZ初始治疗的GBM患者的肿瘤进展和假进展的假设。2.肿瘤具有可变水平的多药耐药性，这降低了药物治疗的有效性。我们将通过分析[11 C]-维拉帕米动力学来定量P-糖蛋白的转运活性，这是治疗耐药和失败的可疑原因。我们将检验新辅助化疗后肿瘤Pgp活性上调的患者生存期和进展时间较短的假设。3.缺氧是使用[18F]-FMISO成像的重要抵抗因素。在脑肿瘤患者中，我们将检验以下假设：初次手术后的FMISO图像定义了局灶性增强RT的适当靶点，这将改善肿瘤进展时间和生存率。在ER阴性转移性乳腺癌患者中，我们将比较缺氧程度与全身治疗反应和无进展生存期。其他实验将比较FMISO和[64 Cu]-ATSM，我们将使用FMISO测试-再测试方案和BOLD-MRI测量时间变化，以寻找肿瘤局部氧合的短期变化。4.本项目将测试18F-FES PET在既往治疗方案失败且正在考虑接受补救性内分泌治疗的ER+乳腺癌患者中选择治疗的用途，并使用FES PET测量局部ER作为内分泌治疗的药效学反应，使用FDG PET定位活动性肿瘤并确定药物治疗（包括HER 2和ER）的早期效应。该项目还将对前列腺癌中的雄激素受体功能进行成像，以识别异质性AR表达。5.临床前放射性药物开发与研究。将开发新的方法来成像肿瘤表型的重要方面。有些是新分子，有些是旧分子的新应用，所有这些都是为了开发有前途的成像剂来表征肿瘤表型。这些包括作为治疗乳腺癌的因子的HER 2的配体、用于雄激素生物学成像的新药剂、用于选择前列腺腺癌新临床试验的患者的单胺氧化酶A配体以及比较Cu-ATSM和FMISO的不同摄取机制的研究。

This program tests molecular imaging variables, how they predict response to therapy, and how they change over the course of different treatments. We propose 5 interactive projects: 1. Proliferation studies to validate how well FLT compares to TdR in patients with a variety of tumors and explores ways to simplify the PET procedure and still distinguish flux from transport. Our hypothesis is that FLT with appropriate data analysis can be as accurate as TdR for reporting tumor proliferation. We will test the hypothesis that FLT PET plus MRI can distinguish between tumor progression and pseudoprogression in patients with GBM that finish initial therapy with external beam RT plus concurrent TMZ. 2. Tumors have variable levels of multi-drug resistance that reduces effectiveness of drug treatments. We will quantify transporter activity of P-glycoprotein as a suspected cause of treatment resistance and failure by analyzing [11C]-verapamil kinetics. We will test the hypothesis that pts who up-regulate their tumor Pgp activity after neoadjuvant chemotherapy will have shorter survival and time to progression. 3. Hypoxia is an important resistance factor that is imaged using [18F]-FMISO. In pts with brain tumors we will test the hypothesis that FMISO images following initial surgery define an appropriate target for focal boost RT that will improve time to tumor progression and survival. In pts with ER-neg metastatic breast cancer, we will compare the extent of hypoxia to response to systemic therapy and progression-free survival. Other experiments will compare FMISO and [64Cu]-ATSM and we will measure temporal changes using an FMISO test-retest protocol and BOLD-MRI to look for short term changes in regional oxygenation of tumors. 4. This project will test the use of 18F-FES PET to choose therapy in pts with a history of ER+ breast cancer who have failed prior regimens and are being considered for salvage endocrine therapy and use FES PET to measure regional ER as a pharmacodynamic response to endocrine therapy and FDG PET to localize active tumor and identify early effects of drug therapy, including HER2 and ER. The project will also image androgen receptor function in prostate cancer to identify heterogeneous AR expression. 5. Preclinical radiopharmaceutical development and research. New methods will be developed to image important aspects of the tumor phenotype. Some are new molecules; some are new applications for old molecules; all to develop promising imaging agents for characterizing the tumor phenotype. These include ligands for HER2 as a factor in treating breast cancer, new agents for imaging of androgen biology, a monoamine oxidase A ligand to select patients for a new clinical trial for prostate adenocarcinoma and studies comparing Cu-ATSM and FMISO for different mechanisms of uptake.